Perrigo launches generic version of Neptazane tablets Perrigo has launched methazolamide tablets, the generic equivalent to Neptazane tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals last June. Methazolamide tablets are indicated for the treatment of several ocular conditions. Estimated annual sales are approximately $12M.
Perrigo announces launch of generic version of Astellas' Protopic ointment Perrigo announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced. Protopic Ointment is indicated to treat moderate to severe eczema. Brand sales were approximately $176M over the last 52 weeks according to Symphony Health Solutions.
Perrigo files to sell $900M in ordinary shares Perrigo intends to use the net proceeds of the offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition of Omega Pharma Invest NV and to repay or refinance certain indebtedness of Perrigo and/or Omega. If the Acquisition is not consummated, then the net proceeds of the offering will be used for general corporate purposes. J.P. Morgan, Barclays and BofA Merrill Lynch are the joint book-running managers in the offering.